Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

@article{Teachey2009MammalianTO,
  title={Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.},
  author={David Teachey and Stephan A. Grupp and Valerie I. Brown},
  journal={British journal of haematology},
  year={2009},
  volume={145 5},
  pages={569-80}
}
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, protein synthesis, and cell-cycle progression through interactions with a number of signalling pathways, including PI3K/AKT, ras, TCL1, and BCR/ABL. Many haematological malignancies have aberrant activation of the mTOR and related signalling pathways. Accordingly, mTOR inhibitors, a class of signal transduction inhibitors that were originally developed as immunosuppressive… CONTINUE READING